Lancashire and South Cumbria
Formulary
Formulary
3 Respiratory system
When prescribing inhalers the drug, device (e.g. MDI, Easibreathe, Autohaler, Accuhaler), strength (micrograms per inhalation), number of puffs per dose and frequency MUST be specified
03-03-03 Phosphodiesterase type-4 inhibitors
| Roflumilast Daxas® |
|
Formulary
|
Tablets 250 microgram, 500 microgram |
 MHRA safety information on risk of suicidal behaviour NICE TA 244: Chronic obstructive pulmonary disease - roflumilast (only as part of a trial) NICE TA461: Roflumilast for treating chronic obstructive pulmonary disease |
|
Links
- NICE TA10: Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma
Asthma action plan child: Asthma UK- Asthma management plan: Asthma UK
- LSCMMG: Asthma Treatment Guideline for Adults
- LSCMMG: Asthma Treatment Guideline for Children
- LSCMMG: COPD Desktop Guideline
- MART asthma plan
- MHRA Drug Safety Update :Nebulised asthma rescue therapy in children: home use of nebulisers in paediatric asthma should be initiated and managed only by specialists
- MHRA safety information on risk of suicidal behaviour
- MHRA: Pressurised metered dose inhalers (pMDI): risk of airway obstruction from aspiration of loose objects
- NICE NG115: Chronic obstructive pulmonary disease in over 16s: diagnosis and management
- NICE NG209: Tobacco: preventing uptake, promoting quitting and treating dependence
- NICE NG80:Asthma: diagnosis, monitoring and chronic asthma management
- NICE TA 244: Chronic obstructive pulmonary disease - roflumilast (only as part of a trial)
- NICE TA38: Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years)
- NICE TA461: Roflumilast for treating chronic obstructive pulmonary disease